Height benefit of GnRH agonists after age 8 in a Portuguese cohort of central precocious puberty
Authors' conclusion
Treatment with GnRHa improved final height in all girls with iCPP, even when initiated after 8 years. To achieve better outcomes, treatment should be provided promptly after diagnosis.
Study context
- Population
- Portuguese girls with idiopathic central precocious puberty (iCPP) who completed gonadotropin-releasing hormone agonists (GnRHa) treatment between 2010 and 2021
- Participants
- 134 participants
- Exposure
- GnRHa started <8 years vs ≥8 years
- Early treatment (ET)n = 48
- Later treatment (LT)n = 86reference
- Outcome
- Growth outcomes (height gain, predicted adult height) with GnRHa by age at treatment onset
- Follow-up
- End of treatment
Methodological detailslongitudinal
- Longitudinal
Main finding
As reported in the abstract
Height gain
- Predicted adult height increased in both groups (ET p = .032; LT p = .04)
- Bone age significantly slowed in all participants (p = .008, p = .034)
- ET vs LT: P = 0.065
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Tanner IV at presentation · baselineMore frequent in LT | P = 0.003 |
Tanner IV at presentation · baseline
- Most children in both groups presented with Tanner II and III
Original publication
Height benefit of GnRH agonists after age 8 in a Portuguese cohort of central precocious puberty. Clin Endocrinol (Oxf). Published 6 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →